The Role of Vasodilating β-Blockers in Patients with Hypertension and the Cardiometabolic Syndrome

American Journal of Medicine

Volumn 123, Issue 7 SUPPL., 2010, Pages

  Taylor, Addison A ^a   Bakris, George L ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Blockers; Cardiometabolic syndrome; Diabetes mellitus; Hypertension; Nebivolol; Vasodilating blockers

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLUCOSE; LABETALOL; LOSARTAN; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; PINDOLOL; PLACEBO; PROPRANOLOL; RENIN INHIBITOR;

ADD ON THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOMETABOLIC SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ESSENTIAL HYPERTENSION; HEART DISEASE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; TREATMENT RESPONSE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; VASODILATOR AGENTS;

EID: 77953656012     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.04.015     Document Type: Article

References (39)

1. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28 (2005) 2745-2749
2. Ballantyne C.M. Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?. Crit Pathw Cardiol 6 (2007) 41-45
3. Manrique C.M., Lastra G., Palmer J., Stump C.S., and Sowers J.R. Hypertension-a treatable component of the cardiometabolic syndrome: challenges for the primary care physician. J Clin Hypertens (Greenwich) 8 suppl 1 (2006) 12-20
4. Conen D., Ridker P.M., Mora S., Buring J.E., and Glynn R.J. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J 28 (2007) 2937-2943
5. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., and Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med 342 (2000) 905-912
6. Smith Jr. S.C. Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 120 suppl 1 (2007) S3-S11
7. Golden S.H., Folsom A.R., Coresh J., Sharrett A.R., Szklo M., and Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the Atherosclerosis Risk in Communities Study. Diabetes 51 (2002) 3069-3076
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
9. Holman R.R., Paul S.K., Bethel M.A., Neil H.A., and Matthews D.R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359 (2008) 1565-1576
10. Kjeldsen S.E., Naditch-Brule L., Perlini S., Zidek W., and Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 26 (2008) 2064-2070
11. Cutler J.A., and Davis B.R. Thiazide-type diuretics and β-adrenergic blockers as first-line drug treatments for hypertension. Circulation 117 (2008) 2691-2705
12. Chobanian A.V., Bakris G.L., Black H.R., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 289 (2003) 2560-2572
13. Messerli F.H., Bangalore S., and Julius S. Risk/benefit assessment of β-blockers and diuretics precludes their use as first-line therapy in hypertension. Circulation 117 (2008) 2706-2715
14. 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 43 (1994) 455-461
15. Pollare T., Lithell H., Selinus I., and Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298 (1989) 1152-1157
16. Kasiske B.L., Ma J.Z., Kalil R.S.N., and Louis T.A. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122 (1995) 133-141
17. Celik T., Iyisoy A., Kursaklioglu H., et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 24 (2006) 591-596
18. Jacob S., Rett K., and Henriksen E.J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents?. Am J Hypertens 11 (1998) 1258-1265
19. Bakris G.L., Fonseca V., Katholi R.E., et al., GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
20. Luna B., and Feinglos M.N. Drug-induced hyperglycemia. JAMA 286 (2001) 1945-1948
21. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
22. Dahlöf B., Sever P.S., Poulter N.R., et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
23. Elliott W.J., and Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369 (2007) 201-207
24. Bangalore S., Parkar S., Grossman E., and Messerli F.H. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100 (2007) 1254-1262
25. 1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 141 (2004) 413-420
26. 1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hypertens 18 suppl 4s (2005) 51A-52A
27. Brixius K., Bundkirchen A., Bölck B., Mehlhorn U., and Schwinger R.H. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 133 (2001) 1330-1338
28. Weber M.A. The role of the new β-blockers in treating cardiovascular disease. Am J Hypertens 18 pt 2 (2005) 169S-176S
29. Mason P.R., Kubant R., Jacob R.F., Walter M.F., Boychuk B., Malinski T., et al. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 48 (2006) 862-869
30. Cockcroft J.R., Chowienczyk P.J., Brett S.E., et al. Nebivolol vasodilates human forearm vasculature: evidence for an l-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 274 (1995) 1067-1071
31. Steinberg H.O., and Baron A.D. Vascular function, insulin resistance and fatty acids. Diabetalogia 45 (2002) 623-634
32. Poirier L., Cléroux J., Nadeau A., and Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19 (2001) 1429-1435
33. Fogari R., Zoppi A., Lazzari P., et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 11 (1997) 753-757
34. Kaiser T., Heise T., Nosek L., Eckers U., and Sawicki P.T. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 24 (2006) 1397-1403
35. Sarafidis P.A., and Bakris G.L. Metabolic effects of β-blockers: importance of dissociating newer from conventional agents. J Hypertens 25 (2007) 249-252
36. Flather M.D., Shibata M.C., Coats A.J.S., et al., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
37. Rosei E.A., and Rizzoni D. Metabolic profile of nebivolol, a β-adrenoceptor antagonist with unique characteristics. Drugs 67 (2007) 1097-1107
38. Giles T. Glucose control in hypertensive patients treated with the vasodilating, selective β-blocker, nebivolol. South Med J 101 (2008) 863 Poster CAR-4
39. Sowers J., and Whaley-Connell A. Long-term effects of the novel β-blocker, nebivolol, on blood glucose in hypertensive patients. South Med J 101 (2008) 863 Poster CAR-3